Abstract
Eptinezumab (Vyepti) is a new CGRP monoclonal antibody for migraine prophylaxis that is administered by intravenous infusion. This article discusses its place in therapy, clinical trial efficacy and adverse effects.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have